BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15673656)

  • 1. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
    Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
    J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).
    Eslamboli A; Cummings RM; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Kirik D; Annett LE
    Exp Neurol; 2003 Nov; 184(1):536-48. PubMed ID: 14637123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
    Georgievska B; Kirik D; Björklund A
    Exp Neurol; 2002 Oct; 177(2):461-74. PubMed ID: 12429192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
    McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
    Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
    Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
    Kirik D; Rosenblad C; Bjorklund A; Mandel RJ
    J Neurosci; 2000 Jun; 20(12):4686-700. PubMed ID: 10844038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ; Snyder RO; Leff SE
    Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system.
    Georgievska B; Kirik D; Björklund A
    J Neurosci; 2004 Jul; 24(29):6437-45. PubMed ID: 15269253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
    Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA; Su C
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
    Aoi M; Date I; Tomita S; Ohmoto T
    Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
    Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
    Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
    Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
    Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
    Kirik D; Georgievska B; Rosenblad C; Björklund A
    Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
    Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
    Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.